Covered recipient · General Payments record
ALIREZA MEYSAMI
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
General Payments · PY2019–2024
$49,450.13
- Reported across 59 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $15,934.81 | 5 |
| Travel and Lodging | $838.87 | 3 |
| Food and Beverage | $469.38 | 8 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $16,898.68 | 11 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $134.44 | 1 |
| Janssen Biotech, Inc. | $94.92 | 1 |
| GlaxoSmithKline, LLC. | $89.17 | 2 |
| Acerta Pharma LLC | $25.85 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $258.78 | 03/08/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1111651428 | CMS |
| Amgen Inc. | $487.20 | 03/08/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1111651430 | CMS |
| Amgen Inc. | $25.00 | 03/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111651432 | CMS |
| Amgen Inc. | $50.00 | 03/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111651434 | CMS |
| Amgen Inc. | $50.00 | 03/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111651436 | CMS |
| Amgen Inc. | $92.89 | 03/09/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1111651438 | CMS |
| Amgen Inc. | $6,000.00 | 03/09/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1111651440 | CMS |
| Amgen Inc. | $2,200.00 | 08/27/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1111651442 | CMS |
| Amgen Inc. | $3,000.00 | 10/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1111651448 | CMS |
| Amgen Inc. | $3,850.00 | 11/26/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1111651444 | CMS |
| Amgen Inc. | $884.81 | 11/26/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1111651446 | CMS |
| AstraZeneca Pharmaceuticals LP | $25.85 | 06/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104632919 | CMS |
| GlaxoSmithKline, LLC. | $26.37 | 11/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116327184 | CMS |
| GlaxoSmithKline, LLC. | $62.80 | 11/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116382814 | CMS |
| Janssen Biotech, Inc. | $94.92 | 11/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078758333 | CMS |
| Novartis Pharmaceuticals Corporation | $134.44 | 11/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086961718 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.